Dmd Flashcards

(47 cards)

1
Q

Incidence of dmd and BMD

A

1: 3500 DMD
1: 18000 BMD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Types of DMD mutations and BMD

A

60-65% out of frame deletions 1+exons
5% exon duplication
Rest nonsense or frameshift

BMD = in frame mutations (85%deletions)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Dmd onset and symptoms?

A
Before 5 years 
Progressive muscular weakness-proximal 
Muscular pseudohyoertrophy (chunky calves)
Dilated cardiomyopathy 
Mean age of death 25
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Symptoms BMD

A

Late learning to walk
Muscle weakness around 11
Loose ability t walk 40-50 yrs
No LD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Symptoms female carriers

A
5-10% cramps 
Usually in 30s 
20% dilated cardiomyopathy -5yr echo/ecg 
Proximal weakness and asymmetric 
Carriers of BMD less affected
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Management DMd?

A

Physio and splints to prevent contractures
Scoliosis - surgery
Cardiomyopathy- echo and ecg every 2 years until 10 - annually after

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Management BMD

A

May require walking frames/ wheelchairs

Echo/ECG every 5 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What percentage of mothers of affected are carriers?

A

60% carriers

But 10-20% gonadal mosaicism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Risk to future affected sons if mum NOT carrier?

A

10% affected son
10% risk carrier daughter
Based on results, pedigree and bayes
PND PGD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Mutation rate in dystrophin gene ?

A

~ 1/3 de novo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

3 options for de novo mutations?

A

1) occur in egg at probands conception
2) after conception - mosaic
3) mutation present in mothers egg cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Situation where female has classic dmd?

A

1) an x-autosome translocation alters normal x inactivation
2) Turner syndrome
3) uniparental disomy (2 from ma)
4) skewed x-inactivation
5) father has BMD and mother a carrier

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Location of DYstophin ?

A

Xp21.2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the DAPC and what does it do?

A

Dystrophin associated protein complex

  • Forms links between actin cytoskeleton and the extra cellular matrix
  • stabilises sarcolema during repeated rounds of contraction and relaxation (nb. Muscle integrity)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Dystrophin domains?

A

FOUR

1) amino terminal (binds actin filaments)
2) rod like domain- 24 spectrin-like triple helical coiled coils (much dispensable)
3) cysteine rich domain
4) carboxy terminal - interacts with membrane proteins sarcoglycan and day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Dystrophin levels is DMD and BMD?

A

Dmd- virtually absent

BMD- 10-40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Pathogenesis of lack of dystrophin?

A
  • disruption of link between cytoskeleton actin and extracellular matrix
  • cell membrane is fragile and can be mechanically damaged
  • deficiency disrupts subsarcolenmal mitochondria localisation, promotes inefficiency, restricts atp generating capacity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What other DAPC members are implicated in muscle wasting disorders?

A

Laminin alpha2 causes MDC1A

Meridian deficient congenital muscular dystrophy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Size of dystrophin?

A

2.4 Mb - ink 0.3% of genomic sequence present in mature transcript
79 exons
14 kb mRNA

20
Q

How many promoters and how many tissue specific?

A

7 different promoters

3 tissue specific - brain, muscle purkinji(large to small) dif exon 1

21
Q

Hotspots for deletions?

A

Proximal - exons 2-20

Distal - exons 45-55

22
Q

Frameshift hypothesis?

A

Deletions that disrupt the translational reading frame = more severe
Deletions leaving frame intact =milder BMD
Correct for 92% of cases

23
Q

Exceptions to frameshift hypothesis?

A
  • Deletions in protein binding domain are severe even if in frame
  • deletion may affect splicing
  • deletions affecting central rod domain are milder
24
Q

What percentage of dmd/BMD are caused by duplications

A

5-10%

Difficult for frameshift mutation as orientation and position usually not known

25
Percentage point mutations
Dmd 25-35% (usually premature termination codons) | BMD 10-20% ( Missense, splice site, nonsense at 3' end that avoids nonsense mediated decay).
26
What mutations exclusively cause DMD related cardiomyopathy? (DCM)
Mutations that disrupt a muscle specific isoform | Eg. Muscle specific promotor - compensated for in other
27
CK levels for DMD, BMD, DCM, female carriers DMD, female carriers BMD
``` DMD- 100% >10x normal Ck BMD- 100% 5x Dcm- most have increased CI Carrier dmd -50% 2-10x Carrier BMD- 30% 2-10x ```
28
3 non genetic methods to test for DMD
1) cK levels 2) muscle biopsy 3) immunohistochemisty
29
What to expect of dmd muscle biopsy
1) increase in variation of fibre size diameter 2) increase in fibrous connective tissue 3) large rounded hyaline fibres 4) foci of degeneration and regeneration
30
Immunohistochemisty results with anti-dystrophin antibody
Dmd patients show absence of staining | BMD show reduction in staining
31
Steps of MLpA
1) Denaturation 2) hybridisation of adjacent probes 3) ligation of adjacent probes 4) pcr of all lighted probes
32
What are the MLPA kits and what is sensitivity?
P034 exons 1-10 21-30 41-50 61-70 P035 exons 11-20+ promoter, 31-40, 51-60, 71-79 Sensitivity 72%
33
Benefit of array for dmd?
Loss or gain of sequence at intronic breakpoints
34
What percentage of point mutations not detected by Sanger?
2% due to complex rearrangements
35
Alternative to PB seq?
Sequence cDNA from muscle - detect rna mutations - try confirm with DNA but not always possible (i.e. Intronic)
36
Risk of recombination across gene if using micro satellite markers?
10%
37
Normal MLPA?
Only excludes 72% | If clinical diagnosis- can offer seq
38
Pos MLPA?
- If single exon- confirm by second method - Check whether in frame or out using Leiden muscular dystrophy site - if first or last exon deleted- could extend into neighbouring gene
39
If familial mutation is unknown?
MLPA of woman in fam with highest risk. If not identified- linkage
40
If mutation not found in mum?
If fam mutation known- mum gonadal? | If fam not known- carrier risk reduced- bayes
41
Risk of carrier if mum or grandmother of affected (bayes)
2/3 for mum | 1/3 for gran
42
Recombination frequencies calculation?
If none seen- work out ave risk of double recombination between markers and multiplying by % of coding region between markers
43
Antisense oligonucleotides
Alter splicing of dmd precursor mRNA by targeting exons affected by deletion/mutation - cause skipping of targeted exon from mature mRNA = convert dmd to BMD
44
What antisense rna molecule targeted in trial?
Exon 51 skipping in clinical trial (13% of dmd)
45
Prob with antisense rna?
Only transient | Muscle tissue must be present - can't reverse muscle loss
46
How do read through drugs work?
Induce protein making machinery to read through premature stop codons
47
2 types of read through drugs?
Aminoglycoside antibiotics (gentamicin) - can't be administered orally Ataburen (ptc124) non amnioglycoside - orally and less toxic (phase 2)